HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE Drug Patent Profile
✉ Email this page to a colleague
When do Hydralazine, Hydrochlorothiazide W/ Reserpine patents expire, and when can generic versions of Hydralazine, Hydrochlorothiazide W/ Reserpine launch?
Hydralazine, Hydrochlorothiazide W/ Reserpine is a drug marketed by Watson Labs and is included in one NDA.
The generic ingredient in HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE?
- What are the global sales for HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE?
- What is Average Wholesale Price for HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE?
Summary for HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 1 |
| DailyMed Link: | HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE at DailyMed |
Recent Clinical Trials for HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| VA Office of Research and Development | |
| US Department of Veterans Affairs |
See all HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE clinical trials
US Patents and Regulatory Information for HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Watson Labs | HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE | hydralazine hydrochloride; hydrochlorothiazide; reserpine | TABLET;ORAL | 085771-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
